Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.64 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820956 | 0.82 | MET (0.80) | METNTRK1ERBB2EGFRLCK | |
| SCHEMBL4820952 | 0.80 | MET (0.68) | METNTRK1ERBB2EGFRLCK | |
| SCHEMBL4249691 | 0.78 | MET (1.00) | METNTRK1 | |
| SCHEMBL4819864 | 0.77 | MET (0.70) | METNTRK1ERBB2EGFRLCK | |
| SCHEMBL4817297 | 0.75 | MET (0.61) | METNTRK1ERBB2EGFRLCK | |
| SCHEMBL4811569 | 0.74 | MET (1.00) | METNTRK1 | |
| SCHEMBL4823112 | 0.74 | MET (1.00) | METNTRK1 | |
| SCHEMBL4811580 | 0.74 | MET (1.00) | METNTRK1 | |
| SCHEMBL4819894 | 0.74 | MET (0.62) | METNTRK1ERBB2EGFRLCK | |
| SCHEMBL4821164 | 0.73 | MET (0.54) | METNTRK1ERBB2EGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | MET 2109/4885NTRK1 483/4885ERBB2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.